Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1990 1
1998 1
2000 1
2005 1
2006 2
2007 2
2008 3
2011 1
2015 5
2016 2
2017 1
2018 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
Leptin and renal disease.
Briley LP, Szczech LA. Briley LP, et al. Semin Dial. 2006 Jan-Feb;19(1):54-9. doi: 10.1111/j.1525-139X.2006.00119.x. Semin Dial. 2006. PMID: 16423182 Review.
Effect of lapatinib on oral digoxin absorption in patients.
Koch KM, Smith DA, Botbyl J, Arya N, Briley LP, Cartee L, White JH, Beyer J, Dar MM, Chung HC, Chu Q, Bang YJ. Koch KM, et al. Among authors: briley lp. Clin Pharmacol Drug Dev. 2015 Nov;4(6):449-53. doi: 10.1002/cpdd.189. Epub 2015 Jun 2. Clin Pharmacol Drug Dev. 2015. PMID: 27137717 Clinical Trial.
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN. Xu CF, et al. Among authors: briley lp. Clin Cancer Res. 2016 Mar 15;22(6):1371-7. doi: 10.1158/1078-0432.CCR-15-2044. Epub 2015 Nov 6. Clin Cancer Res. 2016. PMID: 26546620 Free PMC article.
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Parham LR, Briley LP, Li L, Shen J, Newcombe PJ, King KS, Slater AJ, Dilthey A, Iqbal Z, McVean G, Cox CJ, Nelson MR, Spraggs CF. Parham LR, et al. Among authors: briley lp. Pharmacogenomics J. 2016 Apr;16(2):180-5. doi: 10.1038/tpj.2015.40. Epub 2015 May 19. Pharmacogenomics J. 2016. PMID: 25987243 Free PMC article. Clinical Trial.
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Spraggs CF, Parham LR, Briley LP, Warren L, Williams LS, Fraser DJ, Jiang Z, Aziz Z, Ahmed S, Demetriou G, Mehta A, Jackson N, Byrne J, Andersson M, Toi M, Harris L, Gralow J, Zujewski JA, Crescenzo R, Armour A, Perez E, Piccart M. Spraggs CF, et al. Among authors: briley lp. Pharmacogenomics J. 2018 May 22;18(3):480-486. doi: 10.1038/tpj.2017.39. Epub 2017 Aug 8. Pharmacogenomics J. 2018. PMID: 28786423 Clinical Trial.
19 results